Capecitabine

• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting
  2023-506662-31-00 Phase II 1 country Fondazione GONO G.I.
• Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting
  2022-502351-60-00 Phase II 1 country Unicancer
• Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting
  2023-506703-26-00 Phase III 1 country Institut Jules Bordet
• A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate… Recruiting
  2023-503295-25-00 Phase II/III 1 country Fondazione GONO G.I.
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting
  2024-512999-35-00 Phase II 1 country Unicancer
• A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan… Recruiting
  2023-508227-13-00 Phase I (FiH) 1 country Exscientia AI Limited
• Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P… Recruiting
  2024-518710-11-00 Phase II 2 countries IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Master protocol of novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction … Recruiting
  2024-510977-27-00 Phase II 1 country AstraZeneca AB
• Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized phase III trial comparing safety a… Recruiting
  2023-508572-11-00 Phase III 1 country Region Skane
• Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting
  2024-511609-44-00 Phase II/III 1 country Institut Regional Du Cancer De Montpellier
• Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsat… Recruiting
  2024-513931-26-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting
  2024-512174-10-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
• OPTIMISE Recruiting
  2023-509814-12-00 Phase II 3 countries Region Midtjylland
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus… Recruiting
  2024-512526-28-00 Phase III 5 countries Catharina Ziekenhuis Stichting
• NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta… Recruiting
  2024-519007-10-00 Phase II/III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 Phase I/II 5 countries AstraZeneca AB
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA) Recruiting
  2024-519075-26-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting
  2024-517719-65-00 Phase II 2 countries Oslo University Hospital HF
• Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r… Recruiting
  2024-516196-32-00 Phase III 2 countries Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• VshoRT-R3: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperatIve treatment in low-moderate risk r… Recruiting
  2024-513920-40-00 Phase I/II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended
  2024-519773-19-00 Phase III 11 countries Astellas Pharma Global Development Inc.
• PRODIGE 33 - BALLAD - Phase III study to evaluate the benefit of adjuvant chemotherapy in small bowel adenocarcinoma. Ended
  2024-515299-11-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon

Showing 73–96 of 155 trials